Fenofibrate for Patients With COVID-19 Requiring Hospitalization
Conditions: Corona Virus Disease (COVID-19); Respiratory Distress Syndrome; SARS-CoV-2 Infection Interventions: Drug: TriCor® 145mg tablets; Other: Usual Care; Other: Placebo Sponsors: Hebrew University of Jerusalem; Barzilai Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2020 Category: Research Source Type: clinical trials
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of DR Worsening
Condition: Diabetic Retinopathy Interventions: Drug: Fenofibrate 160mg; Other: Placebo Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI); Juvenile Diabetes Research Foundation; Roche Pharma AG; The Leona M. and Harry B. Helmsley Charitable Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2020 Category: Research Source Type: clinical trials
Fenofibrate for Patients With COVID-19 Requiring Hospitalization
Conditions: Corona Virus Disease (COVID-19); Respiratory Distress Syndrome; SARS-CoV-2 Infection Interventions: Drug: TriCor® 145mg tablets; Other: Usual Care; Other: Placebo Sponsors: Hebrew University of Jerusalem; Barzilai Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2020 Category: Research Source Type: clinical trials
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of DR Worsening
Condition: Diabetic Retinopathy Interventions: Drug: Fenofibrate 160mg; Other: Placebo Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI); Juvenile Diabetes Research Foundation; Roche Pharma AG; The Leona M. and Harry B. Helmsley Charitable Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2020 Category: Research Source Type: clinical trials
Fenofibrate for Prevention of DR Worsening
Condition: Diabetic Retinopathy Interventions: Drug: Fenofibrate 160mg; Other: Placebo Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI); Juvenile Diabetes Research Foundation; Roche Pharma AG; The Leona M. and Harry B. Helmsley Charitable Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2020 Category: Research Source Type: clinical trials
Fenofibrate for Patients With COVID-19 Requiring Hospitalization
Conditions: Corona Virus Disease (COVID-19); Respiratory Distress Syndrome; SARS-CoV-2 Infection Interventions: Drug: TriCor® 145mg tablets; Other: Usual Care; Other: Placebo Sponsors: Hebrew University of Jerusalem; Barzilai Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2020 Category: Research Source Type: clinical trials
Fenofibrate for Prevention of DR Worsening
Condition: Diabetic Retinopathy Interventions: Drug: Fenofibrate 160mg; Other: Placebo Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI); Juvenile Diabetes Research Foundation; Roche Pharma AG; The Leona M. and Harry B. Helmsley Charitable Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2020 Category: Research Source Type: clinical trials
Fenofibrate for Patients With COVID-19 Requiring Hospitalization
Conditions: Corona Virus Disease (COVID-19); Respiratory Distress Syndrome; SARS-CoV-2 Infection Interventions: Drug: TriCor® 145mg tablets; Other: Usual Care; Other: Placebo Sponsors: Hebrew University of Jerusalem; Barzilai Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2020 Category: Research Source Type: clinical trials
Fenofibrate for Prevention of DR Worsening
Condition: Diabetic Retinopathy Interventions: Drug: Fenofibrate 160mg; Other: Placebo Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI); Juvenile Diabetes Research Foundation; Roche Pharma AG; The Leona M. and Harry B. Helmsley Charitable Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2020 Category: Research Source Type: clinical trials
Fenofibrate for Patients With COVID-19 Requiring Hospitalization
Conditions: Corona Virus Disease (COVID-19); Respiratory Distress Syndrome; SARS-CoV-2 Infection Interventions: Drug: TriCor® 145mg tablets; Other: Usual Care; Other: Placebo Sponsors: Hebrew University of Jerusalem; Barzilai Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2020 Category: Research Source Type: clinical trials
Fenofibrate for Prevention of DR Worsening
Condition: Diabetic Retinopathy Interventions: Drug: Fenofibrate 160mg; Other: Placebo Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI); Juvenile Diabetes Research Foundation; Roche Pharma AG; The Leona M. and Harry B. Helmsley Charitable Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2020 Category: Research Source Type: clinical trials
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of DR Worsening
Condition: Diabetic Retinopathy Interventions: Drug: Fenofibrate 160mg; Other: Placebo Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI); Juvenile Diabetes Research Foundation; Roche Pharma AG; The Leona M. and Harry B. Helmsley Charitable Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2020 Category: Research Source Type: clinical trials
Fenofibrate for Patients With COVID-19 Requiring Hospitalization
Conditions: Corona Virus Disease (COVID-19); Respiratory Distress Syndrome; SARS-CoV-2 Infection Interventions: Drug: TriCor® 145mg tablets; Other: Usual Care; Other: Placebo Sponsors: Hebrew University of Jerusalem; Barzilai Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 10, 2020 Category: Research Source Type: clinical trials
A Prospective Observational Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)
Condition: Hypertriglyceridemia, Metabolic Syndrome Intervention: Drug: Tricor (fenofibrate), 145 mg, film-coated tablet Sponsor: Abbott Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 2, 2020 Category: Research Source Type: clinical trials
